Novartis submitted its application to the FDA for its LBH589 drug, a
treatment for multiple myeloma, in March, and the FDA granted the
drug priority review status in May, reducing the standard 12-month
review period to eight months.
The drug works by blocking a key cancer cell enzyme which causes
cell stress and leads to the death of these cells.
(Reporting by Joshua Franklin; Editing by Sunil Nair)
[© 2014 Thomson Reuters. All rights
Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.